Comparative Pharmacology
Head-to-head clinical analysis: CONCERTA versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONCERTA versus EVEKEO ODT.
CONCERTA vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life of methylphenidate from CONCERTA is approximately 3.5 hours (range 2.5-5.5 hours) in adults; in children, mean half-life is 3-4 hours. The extended-release formulation provides a prolonged clinical effect due to the OROS delivery system, not prolonged half-life.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Primarily renal (77%-87% as unchanged drug and metabolites); metabolic elimination accounts for 13%-23%, with minor biliary excretion (<2%).
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant